Adaptive evolution of extensive drug resistance and persistence in epidemic ST11 KPC-producing Klebsiella pneumoniae during antimicrobial chemotherapy
Open Access
- 31 January 2025
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 69 (1) , e0123524
Abstract
The global rise of carbapenem-resistant Klebsiella pneumoniae , including strains producing K. pneumoniae carbapenemase (KPC) types, poses a significant public health challenge due to their resistance to critical antibiotics. Treatment options for infections caused by KPC-producing K. pneumoniae (KPC-KP) are increasingly limited, particularly as these strains develop resistance to last-line antibiotics such as ceftazidime/avibactam and colistin. This study investigates the evolution of antibiotic resistance and persistence in a series of clonally related ST11 KPC-KP strains isolated from a single patient undergoing extended antimicrobial treatment. The patient, a 47-year-old male with a history of kidney transplantation, developed multiple KPC-KP lung infections during his hospital stay. Resistance to colistin and ceftazidime/avibactam emerged during treatment with these antibiotics. Key resistance mechanisms identified included the integration of IS Kpn26 into mgrB gene, leading to mgrB inactivation and colistin resistance, and the emergence of novel bla KPC-2 variants ( bla KPC-71 and bla KPC-179 ) that confer resistance to ceftazidime/avibactam. Despite the development of colistin resistance in a ceftazidime/avibactam-resistant KPC-KP strain following combination therapy, the patient’s clinical condition significantly improved. Phenotypic assays showed that mgrB disruption in KPC-KP resulted in increased biofilm formation and higher susceptibility to phagocytosis. In mouse models, KPC-KP strains with mgrB disruption showed reduced virulence, increased lung colonization and persistence, and a lower inflammatory response, suggesting that mgrB disruption facilitates the transition from acute infection to colonization. This study highlights the complex interplay between antibiotic resistance and bacterial fitness, offering insights into why some patients experience clinical improvement despite severe drug resistance and incomplete bacterial clearance.Keywords
Funding Information
- MOST | National Natural Science Foundation of China (82202583)
- MOST | National Natural Science Foundation of China (82272374)
This publication has 33 references indexed in Scilit:
- Expansion and transmission dynamics of high risk carbapenem-resistant Klebsiella pneumoniae subclones in China: An epidemiological, spatial, genomic analysisDrug Resistance Updates, 2024
- Prevalence and molecular characteristics of colistin-resistant isolates among clinically isolated carbapenem-resistant Klebsiella pneumoniae in ChinaInternational Journal of Antimicrobial Agents, 2023
- The changing face of Klebsiella pneumoniae carbapenemase: in-vivo mutation in patient with chest infectionThe Lancet, 2022
- Molecular epidemiology of carbapenem-resistant Klebsiella pneumoniae in China, 2016–20The Lancet Infectious Diseases, 2022
- Phylogenetic analysis and virulence determinant of the host-adapted Staphylococcus aureus lineage ST188 in ChinaEmerging Microbes & Infections, 2018
- Low prevalence of MCR-1-producing Klebsiella pneumoniae in bloodstream infections in ChinaClinical Microbiology and Infection, 2018
- Fortifying the barrier: the impact of lipid A remodelling on bacterial pathogenesisNature Reviews Microbiology, 2013
- A peptidomics study reveals the impressive antimicrobial peptide arsenal of the wax moth Galleria mellonellaInsect Biochemistry and Molecular Biology, 2009
- The structural basis of lipopolysaccharide recognition by the TLR4–MD-2 complexNature, 2009
- Sequencing and analysis of the large virulence plasmid pLVPK of Klebsiella pneumoniae CG43Gene, 2004